Copy Number Gain of hsa-miR-569 at 3q26.2 Leads to Loss of TP53INP1 and Aggressiveness of Epithelial Cancers

Cancer Cell

Volumn 26, Issue 6, 2014, Pages 863-879

  Chaluvally Raghavan, Pradeep ^a   Zhang, Fan ^a   Pradeep, Sunila ^a   Hamilton, Mark P ^a   Zhao, Xi ^c,d   Rupaimoole, Rajesha ^a   Moss, Tyler ^a   Lu, Yiling ^a   Yu, Shuangxing ^a   Pecot, Chad V ^a,i   Aure, Miriam R ^c,d   Peuget, Sylvain ^e,f,g   Rodriguez Aguayo, Cristian ^a   Han, Hee Dong ^a   Zhang, Dong ^a   Venkatanarayan, Avinashnarayan ^a   Krohn, Marit ^c,d   Kristensen, Vessela N ^c,d   Gagea, Mihai ^a   Ram, Prahlad ^a   Liu, Wenbin ^a   Lopez Berestein, Gabriel ^a   Lorenzi, Philip L ^a   Børresen Dale, Anne Lise ^c,d   Chin, Koei ^h   Gray, Joe ^h   Dusetti, Nelson J ^e,f,g   McGuire, Sean E ^a,b   Flores, Elsa R ^a   Sood, Anil K ^a   Mills, Gordon B ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e AIX MARSEILLE UNIVERSITY   (France)

^f INSTITUT PAOLI CALMETTES   (France)

^g AIX MARSEILLE UNIVERSITY   (France)

^h Oregon Health and Science University Department of Biomedical Engineering   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CISPLATIN; KI 67 ANTIGEN; MICRORNA; MICRORNA 569; PROTEIN; PROTEIN TP53INP1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; HEAT SHOCK PROTEIN; MIRN-569 MICRORNA, HUMAN; MIRN-569 MICRORNA, MOUSE; NUCLEAR PROTEIN; TP53INP1 PROTEIN, HUMAN; TUMOR PROTEIN 53-INDUCED NUCLEAR PROTEIN 1, MOUSE;

AMPLICON; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE DOSAGE; GENE OVEREXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE CANCER; NONHUMAN; OVARY CARCINOMA; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; ANIMAL; BREAST TUMOR; CHROMOSOME 3; DRUG EFFECTS; EXPERIMENTAL NEOPLASM; GENE AMPLIFICATION; GENE DUPLICATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NEOPLASM; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOMES, HUMAN, PAIR 3; CISPLATIN; FEMALE; GENE AMPLIFICATION; GENE DUPLICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAT-SHOCK PROTEINS; HUMANS; MICE; MICE, NUDE; MICRORNAS; NEOPLASMS, EXPERIMENTAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; NUCLEAR PROTEINS; OVARIAN NEOPLASMS;

EID: 84919477596     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2014.10.010     Document Type: Article

References (44)

1. Bagnoli M., De Cecco L., Granata A., Nicoletti R., Marchesi E., Alberti P., Valeri B., Libra M., Barbareschi M., Raspagliesi F., et al. Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget 2011, 2:1265-1278.
2. Bentink S., Haibe-Kains B., Risch T., Fan J.B., Hirsch M.S., Holton K., Rubio R., April C., Chen J., Wickham-Garcia E., et al. Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. PLoS ONE 2012, 7:e30269.
3. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. Cancer Genome Atlas Research Network.
4. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. Cancer Genome Atlas Research Network.
5. Chi S.W., Zang J.B., Mele A., Darnell R.B. Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 2009, 460:479-486.
6. Ciriello G., Miller M.L., Aksoy B.A., Senbabaoglu Y., Schultz N., Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 2013, 45:1127-1133.
7. Deppert W., Steinmayer T. Metabolic stabilization of p53 in SV40-transformed cells correlates with expression of the transformed phenotype but is independent from complex formation with SV40 large T antigen. Curr. Top. Microbiol. Immunol. 1989, 144:77-83.
8. Eder A.M., Sui X., Rosen D.G., Nolden L.K., Cheng K.W., Lahad J.P., Kango-Singh M., Lu K.H., Warneke C.L., Atkinson E.N., et al. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc. Natl. Acad. Sci. USA 2005, 102:12519-12524.
9. Enerly E., Steinfeld I., Kleivi K., Leivonen S.K., Aure M.R., Russnes H.G., Rønneberg J.A., Johnsen H., Navon R., Rødland E., et al. miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS ONE 2011, 6:e16915.
10. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6:259-269.
11. Flores E.R., Tsai K.Y., Crowley D., Sengupta S., Yang A., McKeon F., Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002, 416:560-564.
12. Freed-Pastor W.A., Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012, 26:1268-1286.
13. Gasco M., Shami S., Crook T. The p53 pathway in breast cancer. Breast Cancer Res. 2002, 4:70-76.
14. Gironella M., Seux M., Xie M.J., Cano C., Tomasini R., Gommeaux J., Garcia S., Nowak J., Yeung M.L., Jeang K.T., et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc. Natl. Acad. Sci. USA 2007, 104:16170-16175.
15. Gommeaux J., Cano C., Garcia S., Gironella M., Pietri S., Culcasi M., Pébusque M.J., Malissen B., Dusetti N., Iovanna J., Carrier A. Colitis and colitis-associated cancer are exacerbated in mice deficient for tumor protein 53-induced nuclear protein 1. Mol. Cell. Biol. 2007, 27:2215-2228.
16. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994, 54:4855-4878.
17. Haakensen V.D., Biong M., Lingjærde O.C., Holmen M.M., Frantzen J.O., Chen Y., Navjord D., Romundstad L., Lüders T., Bukholm I.K., et al. Expression levels of uridine 5'-diphospho-glucuronosyltransferase genes in breast tissue from healthy women are associated with mammographic density. Breast Cancer Res. 2010, 12:R65.
18. Hafner M., Landthaler M., Burger L., Khorshid M., Hausser J., Berninger P., Rothballer A., Ascano M., Jungkamp A.C., Munschauer M., et al. Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell 2010, 141:129-141.
19. Hamilton M.P., Rajapakshe K., Hartig S.M., Reva B., McLellan M.D., Kandoth C., Ding L., Zack T.I., Gunaratne P.H., Wheeler D.A., et al. Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif. Nat. Commun. 2013, 4:2730.
20. Hennessy B.T., Lu Y., Gonzalez-Angulo A.M., Carey M.S., Myhre S., Ju Z., Davies M.A., Liu W., Coombes K., Meric-Bernstam F., et al. A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin Proteomics 2010, 6:129-151.
21. Komurov K., Dursun S., Erdin S., Ram P.T. NetWalker: a contextual network analysis tool for functional genomics. BMC Genomics 2012, 13:282.
22. Landen C.N., Chavez-Reyes A., Bucana C., Schmandt R., Deavers M.T., Lopez-Berestein G., Sood A.K. Therapeutic EphA2 gene targeting invivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005, 65:6910-6918.
23. Langerød A., Zhao H., Borgan Ø., Nesland J.M., Bukholm I.R., Ikdahl T., Kåresen R., Børresen-Dale A.L., Jeffrey S.S. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res. 2007, 9:R30.
24. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
25. Liang J., Nagahashi M., Kim E.Y., Harikumar K.B., Yamada A., Huang W.C., Hait N.C., Allegood J.C., Price M.M., Avni D., et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell 2013, 23:107-120.
26. Muggerud A.A., Hallett M., Johnsen H., Kleivi K., Zhou W., Tahmasebpoor S., Amini R.M., Botling J., Børresen-Dale A.L., Sørlie T., Wärnberg F. Molecular diversity in ductal carcinoma insitu (DCIS) and early invasive breast cancer. Mol. Oncol. 2010, 4:357-368.
27. Muranen T., Selfors L.M., Worster D.T., Iwanicki M.P., Song L., Morales F.C., Gao S., Mills G.B., Brugge J.S. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 2012, 21:227-239.
28. Nanjundan M., Cheng K.W., Zhang F., Lahad J., Kuo W.L., Schmandt R., Smith-McCune K., Fishman D., Gray J.W., Mills G.B. Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis. Mol. Oncol. 2008, 2:164-181.
29. Naume B., Zhao X., Synnestvedt M., Borgen E., Russnes H.G., Lingjaerde O.C., Strømberg M., Wiedswang G., Kvalheim G., Kåresen R., et al. Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol. Oncol. 2007, 1:160-171.
30. Okamura S., Arakawa H., Tanaka T., Nakanishi H., Ng C.C., Taya Y., Monden M., Nakamura Y. p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. Mol. Cell 2001, 8:85-94.
31. Oren M., Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb. Perspect. Biol. 2010, 2:a001107.
32. Pawitan Y., Bjöhle J., Amler L., Borg A.L., Egyhazi S., Hall P., Han X., Holmberg L., Huang F., Klaar S., et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived andvalidated in two population-based cohorts. Breast Cancer Res. 2005, 7:R953-R964.
33. Pradeep C.R., Köstler W.J., Lauriola M., Granit R.Z., Zhang F., Jacob-Hirsch J., Rechavi G., Nair H.B., Hennessy B.T., Gonzalez-Angulo A.M., et al. Modeling ductal carcinoma insitu: a HER2-Notch3 collaboration enables luminal filling. Oncogene 2012, 31:907-917.
34. Pradeep C.R., Zeisel A., Köstler W.J., Lauriola M., Jacob-Hirsch J., Haibe-Kains B., Amariglio N., Ben-Chetrit N., Emde A., Solomonov I., et al. Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions. Oncogene 2012, 31:3569-3583.
35. Schafer Z.T., Grassian A.R., Song L., Jiang Z., Gerhart-Hines Z., Irie H.Y., Gao S., Puigserver P., Brugge J.S. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009, 461:109-113.
36. Sheppard H.M., Corneillie S.I., Espiritu C., Gatti A., Liu X. New insights into the mechanism of inhibition of p53 by simian virus 40 large T antigen. Mol. Cell. Biol. 1999, 19:2746-2753.
37. Stewart S.A., Dykxhoorn D.M., Palliser D., Mizuno H., Yu E.Y., An D.S., Sabatini D.M., Chen I.S., Hahn W.C., Sharp P.A., et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 2003, 9:493-501.
38. Tomasini R., Samir A.A., Vaccaro M.I., Pebusque M.J., Dagorn J.C., Iovanna J.L., Dusetti N.J. Molecular and functional characterization of the stress-induced protein (SIP) gene and its two transcripts generated by alternative splicing. SIP induced by stress and promotes cell death. J.Biol. Chem. 2001, 276:44185-44192.
39. Tomasini R., Samir A.A., Carrier A., Isnardon D., Cecchinelli B., Soddu S., Malissen B., Dagorn J.C., Iovanna J.L., Dusetti N.J. TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity. J.Biol. Chem. 2003, 278:37722-37729.
40. Tomasini R., Seux M., Nowak J., Bontemps C., Carrier A., Dagorn J.C., Pébusque M.J., Iovanna J.L., Dusetti N.J. TP53INP1 is a novel p73 target gene that induces cell cycle arrest and cell death by modulating p73 transcriptional activity. Oncogene 2005, 24:8093-8104.
41. Tothill R.W., Tinker A.V., George J., Brown R., Fox S.B., Lade S., Johnson D.S., Trivett M.K., Etemadmoghadam D., Locandro B., et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 2008, 14:5198-5208. Australian Ovarian Cancer Study Group.
42. Urist M., Prives C. p53 leans on its siblings. Cancer Cell 2002, 1:311-313.
43. Weber-Mangal S., Sinn H.P., Popp S., Klaes R., Emig R., Bentz M., Mansmann U., Bastert G., Bartram C.R., Jauch A. Breast cancer in young women (< or= 35 years): Genomic aberrations detected by comparative genomic hybridization. Int. J. Cancer 2003, 107:583-592.
44. Yang J.H., Li J.H., Jiang S., Zhou H., Qu L.H. ChIPBase: a database for decoding the transcriptional regulation of long non-coding RNAand microRNA genes from ChIP-Seq data. Nucleic Acids Res. 2013, 41:D177-D187.